The AmbioPharm management team has more than two hundred years of cumulative experience in the manufacturing of pharmaceutical-grade peptides.
Executive Director, Founder, & Chairman of the Board
As Founder and Chairman of the Board, Dr. Bai provides oversight of Ambiopharm Inc., covering both USA and China operations.
Dr. Bai is also the Founder, Chairman of the Board, and Chief Executive Officer of Ambio, Inc. Before joining AmbioPharm, he was the President and CEO of American Peptide Company where he built the cGMP manufacturing business during his tenure. He was responsible for peptide process development, scale up, and cGMP manufacturing standards. He was involved in numerous peptide process development projects during his tenure, including the process development and manufacture of a 22-amino acid peptide on a 40kg scale by solution phase chemistry.
Chief Executive Officer
As CEO, Mr. Gregg is responsible for managing operations for AmbioPharm in the USA and China and will also serve on the Board of Directors. Prior to AmbioPharm, he had long and successful career at Bachem, a company specializing in the development and manufacture of peptides and oligonucleotides, where he recently held the position of COO at Bachem Americas. In his extensive career at Bachem, Mr. Gregg has held a variety of positions in peptide manufacturing, quality and compliance, and management. In addition to regulatory and quality experience, his skills include driving business and operational growth and strategic acquisition and integration. He holds an MBA from San Diego State University and a BA in Chemistry from the University of California, San Diego.
Chief Financial Officer
Mr. Kiel is the Chief Financial Officer of Ambio Pharmaceuticals, the parent company of AmbioPharm and Ambio. He was previously a Partner at Deloitte Consulting, one of the nation’s Big Four accounting firms. He holds an MBA from The Ohio State University and was awarded a CPA (now inactive) and Series 7 license.
Mr. Kiel is responsible for the financial health of the organization, including financial reporting, cash management, banking and investor relations, and as a government liaison.
Vice President, Technical Sales
Dr. Pennington serves as AmbioPharm’s Vice President of Technical Sales. He is responsible for technical advice for the contract manufacturing of synthetic peptides, pegylated peptides and peptide protein conjugates to be manufactured as either non-GMP or cGMP including generic peptide APIs and APIs for human clinical trials.
His career has centered around the research and development of peptides. He has participated in numerous programs that have evolved into core requirements of cGMP grade peptides at scales from grams to kilograms. Dr. Pennington was part of the management team with a 20+ year career at Bachem Bioscience followed by more than 7 years as President & CEO at Peptides International.
He has a publication record of more than 130 peer-reviewed papers on the synthesis and development of complex peptides for the treatment of human disease.
Senior Vice President of Quality
Brant Zell has over 40 years of Quality experience with over 8 years of Peptide experience. He has dedicated his career in ensuring patient safety and health through setting and demanding appropriate current good manufacturing practices. Brant has Masters’ degrees in Chemistry, Masters in Business Administration, and Technology Management.
Vice President of Global Research and Development
As Vice President of Global Research and Development, Mr. Zhang is responsible for AmbioPharm’s process development activities. He has more than 20 years’ experience in peptide synthesis and manufacturing, having expertise with both SPPS and LPPS approaches.
Vice President of Manufacturing
As VP of Manufacturing, Mukesh is responsible for the day to day operations and long-term outlook of manufacturing at Ambiopharm, North Augusta. He has worked as a Senior Director, Production for 19+ years at Bachem, Torrance California followed by 9+ years as Senior Management in Manufacturing at Polypeptide Group at Torrance, California. He has managed API projects from Development to Commercial scale through project life-cycle, including various regulatory approval (i.e. FDA, PMDA, EMA), successfully bringing APIs to commercial (Multi-Kilo) scale. He holds a Master’s of Science degree in Organic Chemistry from SP University, India.
Vice President of Sales, Europe
As Vice President of Sales, Kathleen Noack is responsible for leading AmbioPharm’s sales and business development team in Europe.
She has more than 30 years of global sales and business development experience with CDMOs and in the pharmaceutical industry, including more than 20 years in the peptide industry. Kathleen holds a Master’s of Science in Chemistry.
Prior to joining Ambiopharm, she held various business management positions at companies, such as Bachem AG and Senn Chemicals AG, where she was part of the management team.
Vice President of Sales, North America
As Vice President of Sales, Mr. Hutchings is responsible for the Sales leadership in the Americas and Australia. With over 30 years of experience in the Life Science and CDMO industry, he is a client focused professional, striving to develop strong client partnerships to improve human health by providing CMC solutions and supplying high quality APIs to the Pharma and Biotech communities from preclinical through to commercialization.
Prior to Ambiopharm, Mr. Hutchings held various Business Development leadership roles, both in Europe and the US, in companies including Packard Bioscience, RTS LifeSciences (now Azenta), PerkinElmer, Silicon Biosystems and more recently at Bachem Americas as VP of Business Development and Sales and VP, Hd of Global Exclusive API’s.
Senior Vice President of Sales, Asia
Mr. Gary Hu is Senior Vice President of Sales, responsible for the Sales leadership in Asia including India.
Mr. Hu has more than 30 years of experience in peptide/oligo CDMO industry. He is passionate for providing CMC solutions and improving human health by supplying high quality APIs to the Pharma and Biotech communities from preclinical through commercialization.
Prior to Ambiopharm, Mr. Hu held various leadership roles in Business Development, Licensing, Sales, Marketing, and Project Management in Bachem and American Peptide Company. He also served as board member in American Peptide Company and Bachem Japan K.K.